Study on the Evaluation Value of PCSK9 Combined with HMGB1/NETS for Criticality and Early Progression/Short-Term Prognosis in Patients with Acute Ischemic Stroke

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600130900

Enrollment

Unknown

Registered

2026-08-26

Start date

2025-01-25

Completion date

Unknown

Last updated

2026-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic stroke

Interventions

Progression group:None

Non-progression group:None

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >=18 years old; 2.AIS patients who were enrolled in accordance with the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2023 and within 24 hours of onset; 3.All of them underwent craniocerebral CT scanning + craniocerebral CTA + craniocerebral CTP examination after admission to the hospital.

Exclusion criteria

Exclusion criteria: 1.patients using sedatives or anesthetics; 2.oral antiplatelet agents prior to the onset of the disease; 3.history of abnormal platelet counts and function; 4.other hematologic disorders; 5.comorbidity with severe infectious and autoimmune disorders; 6.comorbidity with severe hepatic and renal function abnormalities and a personal history of malignancy; 7.pregnant or puerperal females; 8.lack of clinical data.

Design outcomes

Primary

Measure	Time frame
Non-contrast head CT (for stroke evaluation);28-day neurological function prognosis and survival rate;3-month neurological function prognosis and survival rate;Improved Rankin scoring scale;	—

Secondary

Measure	Time frame
Proprotein Convertase Subtilisin/Kexin Type 9;Citrullinated Histone H3;High Mobility Group Box 1;Platelet Factor 4;Interleukin-6;Tumor Necrosis Factor-alpha;Coagulation profile (including clotting time, activated partial thromboplastin time, International Normalized Ratio (INR), D-dimer, etc.);Complete blood count (red blood cells, platelets, hemoglobin, etc.);Biochemical tests (transaminases, creatinine, cholesterol, triglycerides, etc.);Vital signs (heart rate, blood pressure, respiratory rate, peripheral oxygen saturation, etc.);Neurological examination (NIHSS score items);Past medical history and medication use (history of hypertension, diabetes, cardiovascular disease, venous thrombosis, bleeding, and medication usage, etc.);Personal history (smoking history, alcohol consumption history, etc.);Demographic characteristics (gender, age, educational level, marital status, place of residence, contact telephone number, etc.);	—

Measure

Time frame

Proprotein Convertase Subtilisin/Kexin Type 9;Citrullinated Histone H3;High Mobility Group Box 1;Platelet Factor 4;Interleukin-6;Tumor Necrosis Factor-alpha;Coagulation profile (including clotting time, activated partial thromboplastin time, International Normalized Ratio (INR), D-dimer, etc.);Complete blood count (red blood cells, platelets, hemoglobin, etc.);Biochemical tests (transaminases, creatinine, cholesterol, triglycerides, etc.);Vital signs (heart rate, blood pressure, respiratory rate, peripheral oxygen saturation, etc.);Neurological examination (NIHSS score items);Past medical history and medication use (history of hypertension, diabetes, cardiovascular disease, venous thrombosis, bleeding, and medication usage, etc.);Personal history (smoking history, alcohol consumption history, etc.);Demographic characteristics (gender, age, educational level, marital status, place of residence, contact telephone number, etc.);

—

Countries

China

Contacts

Public ContactWei Wei

West China Hospital of Sichuan University

ww8075@126.com+86 189 8060 6331

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Sep 19, 2026